AuthorsScarffe, J Howard
AffiliationDepartment of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
MetadataShow full item record
AbstractIn the future improvements in the efficacy and safety profiles of the various growth factors in clinical use should be achievable through optimization of dosage schedules. The use of combinations of growth factors to provide hemopoietic support should enable considerable advances to be made in the treatment of hematological and non-hematological malignancies. Growth factors, such as granulocyte-macrophage colony stimulating factor may be used not only to maximize neutrophil recovery after myeloablative therapy, but also to mobilize peripheral blood stem cells prior to harvesting by leukapheresis. Growth inhibitory cytokines such as transforming growth factor-beta and macrophage inflammatory protein-1 alpha may be used to protect normal cells in the bone marrow and other sites where dose-limiting toxicities occur. Therefore, in the next few years, the whole approach to chemoradiotherapy will need to be reconsidered in the light of the dose intensification made possible by improved bone marrow support techniques and advances in other areas of supportive care.
CitationFuture outlook for growth factors. 1993, 4 Suppl 1:27-31 Anticancer Drugs
- Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor.
- Authors: Haas R, Ho AD, Bredthauer U, Cayeux S, Egerer G, Knauf W, Hunstein W
- Issue date: 1990 Feb
- Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.
- Authors: Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G
- Issue date: 1989 Sep 9
- Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
- Authors: Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montaño J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR
- Issue date: 1999 May 15
- Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
- Authors: Yeung AW, Pang YK, Tsang YC, Wong SW
- Issue date: 1994 Apr 1
- Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans.
- Authors: Peters WP, Stuart A, Affronti ML, Kim CS, Coleman RE
- Issue date: 1988 Oct